Babak Moghimi, MD

Children with acute myeloid leukemia (AML), the second most common leukemia in children, face a poor prognosis after relapse and significant toxicity from current CAR T therapy. New treatments are critically-needed to prolong survival for these very high-risk patients. Unlike current CAR T treatment for the most common childhood leukemia, acute lymphoblastic leukemia (ALL), patients with AML experience significant toxicity with CAR T therapy. This is due, in part, to the CAR T’s target appearing on healthy cells and tumor cells, driving the therapy to attack both. Novel treatment approaches are in dire need as current AML CAR T-cells have failed to prolong survival for these very high-risk patients.

Dr. Moghimi and team at Children’s Hospital Los Angeles (CHLA) have developed next-generation AML CAR T-cells with improved precision and persistence that could be a promising tool for treating patients with relapsed/refractory AML. As a combination therapy, Dr. Moghimi’s approach avoids healthy cells and eliminates toxicity, increasing survival. This novel approach could be translated into the clinic for pediatric patients at CHLA.